Table 2.
Potential chemotherapy-associated adverse events during neoadjuvant and adjuvant treatment.
| Neoadjuvant Treatment | Adjuvant Treatment | |||
|---|---|---|---|---|
| AE | Grade 1–2 N = 65 (%) |
Grade 3–4 N = 65 (%) |
Grade 1–2 N = 49 (%) |
Grade 3–4 N = 49 (%) |
| Diarrhea | 21 (32.3) | 3 (4.6) | 26 (53.1) | 1 (2.0) |
| Anorexia | 35 (53.8) | 6 (9.2) | 26 (53.1) | 9 (18.4) |
| Vomiting | 28 (43.1) | 4 (6.2) | 20 (40.8) | 4 (8.2) |
| Nausea | 42 (64.6) | 4 (6.2) | 32 (65.3) | 3 (6.1) |
| Dysphagia | 7 (10.8) | 4 (6.2) | 1 (2.0) | - |
| Constipation | 28 (43.1) | 2 (3.1) | 3 (6.1) | - |
| Stomatitis or mucositis | 36 (55.4) | 5 (7.7) | 18 (36.7) | 1 (2.0) |
| Dyspnea | 4 (6.2) | 1 (1.5) | 4 (8.2) | 2 (4.1) |
| Asthenia | 49 (75.4) | 6 (9.2) | 35 (71.4) | 8 (16.3) |
| Acneiform rash | 55 (84.6) | 5 (7.7) | 33 (67.3) | 4 (8.2) |
| Hand-foot syndrome | 6 (9.2) | 1 (1.5) | 2 (4.1) | - |
| Xerosis | 23 (35.4) | - | 11 (22.4) | - |
| Leukopenia | 37 (56.9) | 4 (6.2) | 25 (51.0) | 1 (2.0) |
| Neutropenia | 31 (47.7) | 18 (27.7) | 26 (53.1) | 5 (10.2) |
| Anemia | 53 (81.5) | 1 (1.5) | 45 (91.8) | 1 (2.0) |
| Thrombocytopenia | 35 (53.8) | - | 16 (32.7) | - |
| Serum AST | 5 (7.7) | - | 3 (6.1) | - |
| Serum ALT | 3 (4.6) | - | 7 (14.3) | - |
| Serum GGT | 17 (26.2) | 1 (1.5) | 18 (36.7) | 1 (2.0) |
| Alkaline phosphatase | 6 (9.2) | - | 8 (16.3) | - |
| Fever | 8 (12.3) | - | 2 (4.1) | - |
| Peripheral neuropathy | 7 (10.8) | - | 4 (8.2) | 1 (2.0) |
| Pain | 16 (24.6) | - | 10 (20.4) | 1 (2.0) |
| Alopecia | 14 (21.5) | - | 8 (16.3) | - |
| Renal insufficiency | 1 (1.5) | 1 (1.5) | 3 (6.1) | 2 (4.1) |
| Infection | 4 (6.2) | 1 (1.5) | 4 (8.2) | 2 (2.1) |
| Thrombosis | 3 (4.6) | 3 (4.6) | - | 1 (2.0) |
| Toxic death | - | - | - | - |
ITT population (n = 65), none had grade 5 toxicities; AE, Adverse Events; ITT, intent-to-treat; AST: aspartate aminotransferase; ALT: alanine aminotransferase.